Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase NA 1

Status

Completed 18Withdrawn 5Terminated 4Recruiting 4Active not recruiting 4Unknown 3Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 51Head & Neck 8Dermatologic 5Breast 3Thoracic 2Tumor-Agnostic 1Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Keratosis, Actinic 3Skin Neoplasms 2Carcinoma, Squamous Cell 2Melanoma 1Carcinoma, Merkel Cell 1

Interventions

Nivolumab 18Ipilimumab 16pembrolizumab 15Cyclophosphamide 13trametinib 9Radiotherapy 8dabrafenib 6Interleukin-2 6sargramostim 5fludarabine phosphate 5aldesleukin 5Vemurafenib 5Peripheral Blood Stem Cell Transplantation 5Fluorouracil 5130-nm albumin-bound paclitaxel 5fludarabine 4Radiosurgery 4Melphalan 4Celecoxib 4encorafenib 3durvalumab 3binimetinib 3avelumab 3Vorinostat 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Leucovorin 3Granulocyte-Macrophage Colony-Stimulating Factor 3Cytarabine 3Capecitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Fluorouracil × Dermatologic × Clear all
NCT04329221 2025-05-07

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Massachusetts General Hospital

Phase 2 Withdrawn
Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms, Keratosis, Actinic

NCT04642287 2025-05-07

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Massachusetts General Hospital

Phase 2 Withdrawn
Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms, Keratosis, Actinic

NCT03167164 2025-02-21

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Dermatologic

Carcinoma, Merkel Cell

NCT03167177 2025-02-21

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Dermatologic

Melanoma

NCT00814528 2018-09-10

Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses

University of Chicago

Phase NA Withdrawn
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡